Tarix Pharmaceuticals
Brookline
Massachusetts
United States
Tel: 617-827-6824
Website: http://www.tarixpharma.com/
Email: rlf629@gmail.com
7 articles about Tarix Pharmaceuticals
-
Tarix Pharmaceuticals Orphan Receives FDA Fast Track Designation For TXA127 As Potential Treatment For Duchenne Muscular Dystrophy
10/6/2015
-
Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia
3/5/2013
-
Unigene Laboratories, Inc. and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
11/27/2012
-
Unigene Laboratories, Inc. and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-Engineered" TXA127
9/19/2012
-
Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension
9/27/2011
-
Tarix Pharmaceuticals Enrolls First Patient in Phase 1 Clinical Study of TXA127 in Adult Patients Following Double Cord Blood Stem Cell Transplant
4/26/2011
-
Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
2/24/2011